Morgan Stanley: Initiates coverage of Innovent Biologics with a "Market Perform" rating and a target price of HKD 95.

GateNews

2025-10-13 02:45:13

On October 13, Jin10 reported that Morgan Stanley published a report, initiating coverage on Innoscience (02577.HK) with a rating of “In Line with Market” and a target price of HKD 95, corresponding to a forecasted price-to-sales ratio of 34 times next year. The bank indicated that Innoscience is a leading manufacturer of gallium nitride power integrated circuits and believes that the company is well-prepared to benefit from secular growth drivers such as artificial intelligence data centers, humanoid Bots, and electric vehicles. However, market competition remains fierce, and the bank believes that the current valuation largely reflects the market's high expectations.

View Original

Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to Disclaimer.

Comment

0/400

No comments